Other Events ·
PDS Biotechnology Corporation announced a strategic refocus of its development portfolio, prioritizing the advancement…
PDSBPDS Biotechnology Corp
PDS Biotechnology Corporation announced a strategic refocus of its development portfolio, prioritizing the advancement of PDS0301, an investigational tumor-targeted immunocytokine for metastatic colorectal cancer. The company will cease internal investment in and discontinue the Phase 3 VERSATILE-003 trial for PDS0101, intending instead to pursue strategic partnerships or externally funded opportunities for its continued development. This decision follows a comprehensive review of capital allocation priorities and aims to maximize long-term shareholder value by concentrating resources on PDS0301, which demonstrated encouraging clinical activity in patients with liver metastases. The company plans to advance PDS0301 through a randomized Phase 2b trial over the next 18 to 24 months while maintaining disciplined capital allocation. PDS Biotechnology is a late-stage immunotherapy company focused on developing targeted cancer treatments.